Scynexis, Inc.
A biotechnology company in Jersey City, New Jersey, that develops medicines for hard-to-treat infections and rare diseases. Its best-known product is Brexafemme, an oral pill for vaginal yeast infections that was the first new class of antifungal drug approved by the FDA in more than twenty years. The company began in 1999 as a chemistry-and-automation services firm called ScyRex, later renamed SCYNEXIS, and today also works on treatments for polycystic kidney disease.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Great Point Partners, LLC | 13G/APassive | 9.99% | 4.08M | Aug 14, 2026 |
| Dr. Jeffrey R. Jay, M.D. | 13G/APassive | 9.99% | 4.08M | Aug 14, 2026 |
| Ms. Lillian Nordahl | 13G/APassive | 9.99% | 4.08M | Aug 14, 2026 |
| CVI Investments, Inc. | 13G/APassive | 5.9% | 615.5K | Aug 14, 2026 |
| Heights Capital Management, Inc. | 13G/APassive | 5.9% | 615.5K | Aug 14, 2026 |
| Adage Capital Management, L.P. | 13GPassive | 9.99% | 1.04M | Aug 12, 2026 |
| Robert Atchinson | 13GPassive | 9.99% | 1.04M | Aug 12, 2026 |
| Phillip Gross | 13GPassive | 9.99% | 1.04M | Aug 12, 2026 |
| Federated Hermes, Inc. | 13G/APassive | 4.03% | 441.7K | Jul 20, 2026 |
| Voting Shares Irrevocable Trust | 13G/APassive | 4.03% | 441.7K | Jul 20, 2026 |